As end of New York opioid trial nears, AbbVie’s Allergan ponies up $200M to settle its part of the case
On the day of closing arguments in a high-profile New York opioid trial, AbbVie has inked a $200 million settlement to put the case to bed.
AbbVie's Allergan has agr...
Continue Reading →
